Navigation Links
OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
Date:8/12/2009

CaPRI implant achieves significant drop in intraocular pressure; company advances to next generation of device, new trials

San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials for their first device with favorable preliminary safety and tolerability. As a result, the company is now moving forward with a more sophisticated design of the device, with plans to launch new clinical trials later this year.

Dr. Bernard Press, president of OcumatRx, said that after years of research and development, the CaPRI device, named after its inventor, Dr. David Castillejos, ophthalmologist, who pioneered the pressure reduction implant (PRI) technology, showed significant results in lowering intraocular pressures during recent trials conducted in Mexico. During the trials involving 10 patients aged from 40 to 75, the first generation of the CaPRI device was inserted into one eye and the other eye was used as the control.

Press said the subjects were tested over a 12 month period and at the end of the trial the average drop in pressure was 6.4 millimeters, an achievement which is better than the current standard of care for increased intraocular pressure, which is using prescription drops.

"We are encouraged by the early results and are now finalizing the next generation of the device, designed by Dr. Castillejos after further research and development," said Press. "For glaucoma patients, having a permanent implant has the potential to stabilize pressure without the need for expensive drops, which can lose efficacy over time."

The CaPRI is inserted in a minimally invasive procedure, stabilizes intra-ocular pressure and stops the progression of Glaucoma in the early stages, before it begins advancing toward tunnel vision and eventual blindness, according to Dr. Castillejos, chief medical officer of OcumatRx. By taking advantage of the unique shape of the device, it creates multiple draining sites, thus decreasing the chance of scar tissue, blocking the effect of the device and improving stability of the implant.

Castillejos is working with custom device manufacturers on the technologically advanced new design.

"The second generation device can be implanted more easily, adds more surface area and we believe it will increase both effectiveness and patient comfort," said Dr. Castillejos. "As soon as we complete evaluation of a new prototype, we will be scheduling a series of pre-clinical and clinical trials as soon as possible. Since advanced Glaucoma is the second leading cause of blindness in the world, and current therapies are neither highly effective nor free of side effects, we feel a sense of urgency to advance the clinical trials and realize our long-term goal of developing and marketing a permanent treatment."

Given the results of the clinical trials this year in foreign countries, OcumatRx will be filing to market the new device in Europe and Asia in early 2010 while it pursues the clinical and regulatory steps necessary to market in the U.S. and other countries, Press said.

About OcumatRx
Founded in 2004 by several leading ophthalmologists and research scientists in the San Diego area, OcumatRx has pioneered the development of a medical device that represents a new concept for the permanent treatment of patients with Glaucoma. For more information, see www.ocumatrx.com.

Contacts:

Gable PR - 619-284-1714
Tom Gable
tom(at)gablepr.com
619-251-3881 cell

Liz Dill
liz(at)gablepr.com
720-732-0147 cell         

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2740024.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Preferred Health Technology Announces Support for MGMAs Project SwipeIT
2. International Isotopes Inc. Announces Second Quarter and Six Months 2009 Financial Results
3. Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured
4. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
5. Beckman Coulter Announces the Creation of Beckman Coulter Genomics
6. The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms
7. Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
8. 3SBio Inc. Announces Unaudited Second Quarter 2009 Results
9. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
10. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
11. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... Charlotte, NC (PRWEB) , ... December 08, 2016 ... ... repeal Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass ... A story movement gives people ongoing opportunities to share their unfortunate experiences; such ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally ... commercial clients in the northern Alabama and Georgia regions, is embarking on a ... Nobis Works has built a network of support and education facilities to develop ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: